> Products > L-Lysine API

China L-Lysine API Factory

We stick with the theory of "quality very first, support 1st, continual improvement and innovation to fulfill the customers" for that management and "zero defect, zero complaints" as the quality objective. To excellent our company, we provide the merchandise together with the great good quality at the reasonable cost for L-Lysine API,CAS NO 57282-49-2,57282-49-2,L-Lysine, We hope we could have a helpful romantic relationship with businessman from all over the globe.
L-Lysine API, With excellent merchandise, high quality service and sincere attitude of service, we ensure customer satisfaction and help customers create value for mutual benefit and create a win-win situation. Welcome customers all over the world to contact us or visit our company. We are going to satisfy you with our expert service!

Hot Products

methyl 1-bromo-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate
Product Name:methyl 1-bromo-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate
Molecular Formula:C17H12BrNO4
Molecular Weight:374.19
CAS Registry Number:1455091-21-0
Resmetirom
Product Name:Resmetirom
Molecular Formula:C17H12Cl2N6O4
Molecular Weight;435.22
CAS Registry Number;920509-32-6
Diethyl L-glutamate hydrochloride
Product Name:Diethyl L-glutamate hydrochloride
Molecular Formula:C9H18ClNO4
Molecular Weight:239.7
CAS Registry Number:1118-89-4
(S)-4-N-Boc-2-methylpiperazine
Product Name:(S)-4-N-Boc-2-methylpiperazine
Molecular Formula:C10H20N2O2
Molecular Weight:200.28
CAS Registry Number:147081-29-6
4-((2-aMinoethyl)(5-chlorobenzo[d]oxazol-2-yl)aMino)butan-2-one (diMethanesulfonate)
Product Name:4-((2-aMinoethyl)(5-chlorobenzo[d]oxazol-2-yl)aMino)butan-2-one (diMethanesulfonate)
Molecular Formula:C15H24ClN3O8S2
Molecular Weight:473.94936
CAS Registry Number:1276666-12-6
(1S-4R)-4-[[(1,1-diMethylethoxy)carbonyl]aMino]- 2-Cyclopentene-1-carboxylic acid Methyl ester
Product Name:(1S-4R)-4-[[(1,1-diMethylethoxy)carbonyl]aMino]- 2-Cyclopentene-1-carboxylic acid Methyl ester
Molecular Formula:C18H30N2O5
Molecular Weight:354.44
CAS Registry Number:229613-93-8

Related Blog
Reviews

What is the difference between API and FDF in pharma？
In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”
Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry
Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products can be produced in ordinary chemical plants without obtaining a pharmaceutical production license. As long as the technical indicators meet certain level requirements, they can be used to participate in the synthesis and production of drugs.
Prostate Cancer and Darolutamide
Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).
TOP 8 Linezolid intermediate maker
Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.
Gilteritinib Fumarate
Sandoo Pharmaceutica is a professional pharmaceutical intermediates manufacturer. We provide good quality Gilteritinib Fumarate Cas: 1254053-43-4. Welcome and we look forward to your inquiry!
FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC
On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

China L-Lysine API Factory

Related Products

Hot Products

methyl 1-bromo-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate

Resmetirom

Diethyl L-glutamate hydrochloride

(S)-4-N-Boc-2-methylpiperazine

4-((2-aMinoethyl)(5-chlorobenzo[d]oxazol-2-yl)aMino)butan-2-one (diMethanesulfonate)

(1S-4R)-4-[[(1,1-diMethylethoxy)carbonyl]aMino]- 2-Cyclopentene-1-carboxylic acid Methyl ester

What is the difference between API and FDF in pharma？

Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

Prostate Cancer and Darolutamide

TOP 8 Linezolid intermediate maker

Gilteritinib Fumarate

FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

Johnny 2023-05-20 23:45:40

Kimberley 2022-03-30 06:12:20

Dominic 2022-05-25 06:46:18

Gabrielle 2024-05-06 12:57:02

Carlos 2023-12-08 09:24:47

Steven 2024-01-25 07:34:59

Send Inquiry